NIH Zika Vaccine Initial Trial Results Encouraging

Golden, Co. — Jan. 4 , 2017 — PharmaJet, the maker of innovative, needle-free injection technology, was featured on a CBS 60 Minutes segment concerning the National Institutes of Health DNA vaccine clinical trial for the Zika virus.

There are now more than 30,000 diagnosed Zika cases in every state but Alaska, with most of those in the U.S. territory of Puerto Rico. Because it is now known that Zika can be transmitted through mosquitoes, blood and sex, that number is expected to rise.

The vaccine has shown in initial trials that it generates the expected immune response to fight the Zika virus. The plan is to now test the vaccine in thousands of volunteers living in Zika-infected areas like Puerto Rico. “If the vaccine protects people there,” Dr. Anthony Fauci, head of infectious diseases at the NIH told the 60 Minutes reporter, “it could be ready for distribution by early 2018.”

“We are pleased by the encouraging results of the Zika vaccine trial. The PharmaJet needle-free injection device offers a safe, fast and easy-to-use method to deliver the vaccine,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.

For more information on PharmaJet’s needle-free technology, please visit www.staging.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

Menu